title: Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082.
authors.forename: J Hans
authors.initials: JH
authors.lastname: Devries
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009570:Nitriles / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D009570:Nitriles; D011719:Pyrazines; D011759:Pyrrolidines; D014230:Triazoles; D000218:Adamantane